Efficacy of tumor treating fields in high-grade glioma: a real-world retrospective analysis of 28 patients

1

The study evaluated the efficacy of Tumor Treating Fields (TTFields) in 28 patients with high-grade gliomas in a real-world setting.
2

The median duration of TTFields use was 9.4 months, with a median adherence rate of 88.05% among the patients.
3

Newly diagnosed patients had a median progression-free survival (PFS) of 18.1 months and overall survival (OS) of 22.0 months.
4

In the recurrent cohort, median PFS was 9.1 months and OS was 18.2 months, with grade 1–2 dermatologic reactions as the most common adverse events.
5

These findings suggest TTFields therapy is feasible and well tolerated, but further prospective studies with larger cohorts are needed.

Frontiers In Neurology

1